Skip to content

SiSi-trial.

PREVENTION OF SURGICAL SITE INFECTION AT THE GROIN AFTER FEMORAL ARTERIAL EXPOSURE USING LOCAL GENTAMYCIN SPONGE.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28917
Enrollment
608
Registered
2012-12-17
Start date
2012-07-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary endpoint: the incidence of surgical site infection (SSI), including prosthetic graft infection classified according to Szilagyi, through 30 days postoperatively by a committee blinded to study allocation. The primary study comparison will be done in the intention-to-treat population. Secondary endpoints: Isolation of bacteria in colony forming units (CFU), length of hospital stay (LOS

Interventions

The study arm will receive the implantable gentamicin collagen sponge and the control arm will not receive a sponge at the end of the vascular procedure before closing the groin.

Sponsors

Atrium MC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients undergoing longitudinal femoral exposure for a vascular procedure of 18 years and older.

Exclusion criteria

Exclusion criteria: Patients known with a sensitivity or allergy to gentamicin. Patients pregnant or breast feeding. In case of bilateral groin dissection for vascular surgery, the left groin is excluded.

Design outcomes

Primary

MeasureTime frame
The incidence of surgical site infection (SSI), including prosthetic graft infection classified according to Szilagyi, through 30 days postoperatively by a committee blinded to study allocation.

Secondary

MeasureTime frame
Isolation of bacteria in colony forming units (CFU), length of hospital stay (LOS; in days), readmission, reoperation, antibiotics during hospital stay and at home (in days).

Contacts

Public ContactMarit Albada, van
marit_van_albada@hetnet.nl+31 (0)6 53665310

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)